Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Astragaloside IV

Astragaloside IV (Huang Qi Extract) · also known as Astragaloside IV, Astragaloside IV, Astragaloside IV

Astragaloside IV is a cycloartane-type triterpene saponin found in astragalus. Animal studies show it can affect Nrf2/HO-1, eNOS and intestinal tight junction markers, but it has not been confirmed that these pathways are activated in humans.

Typical dose: High-purity astragaloside IV 20–50 mg/day, taken in the morning with a meal. This is not a standard dose with adequate human evidence for efficacy and long-term safety.
Absorption and forms: Ordinary crude astragalus extracts contain very little astragaloside IV (under 0.1%), and it is poorly absorbed orally. Purified products on the market range from 10% to 98% purity, so check the label of the specific product. Oral bioavailability is low, and animal data cannot be taken as directly representative of humans.

Mechanisms of action

Nrf2/ARE activation of endogenous antioxidant enzymes

★★★☆☆Mechanism evidence: grade CSecondary target

In a rat model of renal ischemia-reperfusion, Nrf2 and HO-1 expression in kidney tissue increased after astragaloside IV treatment. Keap1-related effects and a several-fold induction of HO-1 have not been confirmed in humans, and it is also uncertain whether 20–50 mg/day reaches effective concentrations in human tissues.

References (1)
  1. Su 2022 · Rat renal ischemia-reperfusion study: Nrf2 and HO-1 expression in kidney tissue increased after astragaloside IV treatment

Endothelial nitric oxide synthase (eNOS) coupling and NO vasodilation

★★★☆☆Mechanism evidence: grade CSecondary target

Animal experiments show astragaloside IV can change eNOS phosphorylation and nitric oxide production, and related markers in kidney tissue also improved in diabetic rats. The claim that BH4 stabilizes eNOS coupling and prevents uncoupling has not been directly verified in humans at usual doses.

References (1)
  1. Fan 2019 · Diabetic rat study: after oral doses of 5–10 mg/kg/day, kidney eNOS phosphorylation and NO-related markers improved

Epithelial tight junction (ZO-1 / Occludin) reinforcement and barrier repair

★★☆☆☆Mechanism evidence: grade CSecondary target

In an animal colitis model, colonic tight junction markers such as ZO-1 and Occludin improved after oral astragaloside IV. The doses in this model were relatively high, so it cannot be assumed that the dose used here is effective in humans.

References (1)
  1. 2026 study · Mouse colitis study: after oral astragaloside IV, colonic tight junction markers such as ZO-1 and Occludin improved

Safety and drug interactions

People with an autoimmune disease in an acute active phase should first be assessed by their doctor. The available data are not enough to say it is very safe. Data for pregnancy, breastfeeding and long-term use are insufficient, so these groups should use it under a doctor’s guidance.

Immune stimulation

Has immunomodulating effects. Each of these stimulates immune responses. They may counteract immunosuppressant drugs, and caution is also needed during active autoimmune disease.

Open in the interactive app ›